TherapeuticsMD has resubmitted the New Drug Application (NDA) for TX004HR (oestradiol).
Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women (see section 5.1). The experience treating women older than 65 years is limited.
Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women (see section 5.1). Vagirux may be used in women with or without an intact uterus. The experience treating women older than 65 years is limited.
Treatment of vaginal atrophy due to oestrogen deficiency in postmenopausal women aged 50 years and above, who have not had a period for at least 1 year (see section 5.1).
TherapeuticsMD announced that the FDA has approved Imvexxy (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated...